Theralase photo dynamic compounds effective in destruction of drug resistant bacteria

242 views
194 views

Published on

Theralase Photo Dynamic Compounds Effective in Destruction of Drug Resistant Bacteria

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
242
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Theralase photo dynamic compounds effective in destruction of drug resistant bacteria

  1. 1. Theralase Photo Dynamic Compounds Effective in Destruction of Drug Resistant BacteriaToronto, Ontario – October 17, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announcedtoday that its Photo Dynamic Compound (PDC) technology has been proven effective in thedestruction of staphylococcus aureus and its multi drug resistant strain, methicillin resistantstaphylococcus aureus, also known as MRSA.MRSA is a bacteria strain that has grown resistant to antibiotics and hence has the potential ofcausing invasive infections, which are extremely difficult to treat in 25% of the populationinfected. In 2005, the Centers for Disease Control and Prevention reported that 94,000individuals were hospitalized as a result of MRSA infections and there were 18,650 deaths as aresult, costing the US healthcare system an additional $45 billion a year.The scientific data supporting this discovery was presented yesterday at the 9th InternationalSymposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in Brixen,Italy. The presentation by Dr. Lothar Lilge confirms the significance of the research conductedby Theralase’s and University Health Network’s (UHN) scientists.Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, “Theralase unveiled tothe scientific community its advanced sterilization platform technology that is able to deliver an8 log or 99.999999% kill rate, which is comparable with complete sterilisation of life threateninginfectious microorganisms, such as staphylococcus aureus and MRSA. Theralase’s new PDCtechnology would therefore be well suited to preventing hospital acquired infections, as well asinfections found in nursing homes, schools or bacterial contaminations in food processingfacilities. Quite simply, once MRSA bacteria have been detected, they could be quicklydestroyed utilizing Theralase’s patented Photo Dynamic Compounds and proprietary lightsources.”Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre,UHN stated, “Theralase’s PDCs in conjunction with light exposure were shown to achieveessentially complete sterilization, even at low concentrations, against staphylococcus aureusand MRSA in an in vitro laboratory setting. The effective dose of tested PDCs was not toxic forhuman tissues even after 4 hours of incubation demonstrating their suitability and safety tosterilization applications. As an added benefit, the Theralase PDCs maintained their sterilizingactivity even in low oxygen conditions demonstrating a Type I photosensitization effect thatmay open up new opportunities for the safe and effective destruction of many strains of deadlyorganisms and tumours that thrive in low oxygen environments, such as cancer.”Dr. Arkady Mandel went on to say, “The dramatic increase of antibiotic resistance in bacteriahas led me to investigate whether Theralase’s PDCs would be effective in the destruction ofMRSA, as an alternative to antibacterial pharmaceutical drugs. Our successes to date will allowTheralase’s PDCs to be used in the future to combat difficult to heal invasive infections. The
  2. 2. Theralase PDCs in these studies have been chosen for their low dark toxicity to human tissueand for their high cancer and bacteria targeting properties. The Theralase PDCs are extremelypromising for the development of advanced disinfection and sterilization strategies forcontrolling and eliminating hospital and community acquired infections, such as MRSA.”Roger Dumoulin-White, President and CEO of Theralase stated, “Based on our recent successeswith our PDC technology in destroying MRSA, Theralase is actively pursuing earlycommercialization of this technology through strategic partnerships to co-develop thetechnology for particular sterilization applications. As an added benefit, due to the very lowconcentrations of PDCs required for sterilization, the costs of administering this technology willbe very cost effective. The early commercialization of our patented PDC technology withstrategic partners will dramatically improve the financial revenues of the organization. Thesescientific studies thus highlight Theralase’s commitment to advancing its exclusive patentedtechnologies for the ultimate goal of greater commercial opportunities for the Company.”About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and marketspatented, superpulsed laser technology utilized in biostimulation and biodestructionapplications. Theralase technology is safe and effective in treating pain, inflammation and fortissue regeneration of neural muscular skeletal conditions and wound healing. Theralase iscurrently developing patented Photo Dynamic Compounds (PDCs) that are able to target anddestroy cancers, bacteria and viruses when light activated by Theralase’s proprietary andpatented laser technology.For further information please visit www.theralase.com, regulatory filings may be viewed byvisiting www.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims anyobligation to update these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information:Roger Dumoulin-WhitePresident & Chief Executive Officer416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comArkady Mandel
  3. 3. Chief Scientific Officer416-447-8455 ext. 242amandel@theralase.comGreg BewshDirector of Investor Relations416-447-8455 ext. 262gbewsh@theralase.com

×